Search

Coloplast A-S (Class B)

Chiusa

569.8 -0.9

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

564.4

Massimo

579.4

Metriche Chiave

By Trading Economics

Entrata

70M

875M

Vendite

2M

7B

P/E

Media del settore

35.807

90.831

EPS

3.88

Rendimento da dividendi

4.01

Margine di Profitto

12.572

Dipendenti

16,744

EBITDA

2B

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+11.86% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

4.01%

2.20%

Utili prossimi

6 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

7.5B

130B

Apertura precedente

570.7

Chiusura precedente

569.8

Coloplast A-S (Class B) Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 gen 2026, 19:05 UTC

I principali Market Mover

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13 gen 2026, 23:41 UTC

Discorsi di Mercato

Nikkei May Rise on Japan Election Hopes -- Market Talk

13 gen 2026, 23:41 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

13 gen 2026, 23:33 UTC

Discorsi di Mercato

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13 gen 2026, 23:13 UTC

Acquisizioni, Fusioni, Takeovers

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13 gen 2026, 23:10 UTC

Acquisizioni, Fusioni, Takeovers

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13 gen 2026, 23:03 UTC

Discorsi di Mercato

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13 gen 2026, 21:50 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13 gen 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

13 gen 2026, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13 gen 2026, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13 gen 2026, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13 gen 2026, 21:15 UTC

Acquisizioni, Fusioni, Takeovers

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13 gen 2026, 21:08 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13 gen 2026, 20:39 UTC

Discorsi di Mercato

Silver Settles at Another New High -- Market Talk

13 gen 2026, 20:21 UTC

Discorsi di Mercato

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13 gen 2026, 20:17 UTC

Discorsi di Mercato

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13 gen 2026, 19:08 UTC

Acquisizioni, Fusioni, Takeovers

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13 gen 2026, 19:03 UTC

Utili

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13 gen 2026, 18:50 UTC

Utili

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13 gen 2026, 17:54 UTC

Discorsi di Mercato

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13 gen 2026, 17:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Equities Roundup: Market Talk

13 gen 2026, 17:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13 gen 2026, 17:49 UTC

Discorsi di Mercato

Analysts Call For Potential Record Ethanol Output -- Market Talk

13 gen 2026, 17:38 UTC

Discorsi di Mercato

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13 gen 2026, 17:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

13 gen 2026, 17:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

13 gen 2026, 17:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

13 gen 2026, 17:19 UTC

Discorsi di Mercato

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13 gen 2026, 17:15 UTC

Discorsi di Mercato

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Coloplast A-S (Class B) Previsione

Obiettivo di Prezzo

By TipRanks

11.86% in crescita

Previsioni per 12 mesi

Media 901.38 DKK  11.86%

Alto 1,056 DKK

Basso 720 DKK

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Coloplast A-S (Class B) - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

8 ratings

2

Acquista

4

Mantieni

2

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat